Infographic: Here, we share the top 5 oncology news stories we reported this week, including the most recent FDA updates and expert insights on key developments in the field.
Targeted Oncologyreports current advancements in cancer research, including interviews with oncology experts, conference coverage, clinical trial results, and the most recent approvals. Check out our weekly roundup below of the biggest news in oncology that we shared this week.
Follow the links below in our infographic to check out the full story.
This week, the FDA announced 2 new approvals for thetreatment of patients with multiple myelomaas well as fordetectingminimal residual diseasein patients with acute lymphoblastic leukemia or multiple myeloma. A roundup of all the FDA news from September 2018is also now available.
During aTargeted Oncologylive case-based peer perspectives presentation, Rachel Sanborn, MD, director of Thoracic Oncology, Providence Cancer Center, discussed treatment options forpatients with nonsmall cell lung cancer(NSCLC).
In an interview, Javier A. Pinilla-Ibarz, MD, PhD, a senior member of Moffitt Cancer Center, discussed the current treatment landscape for chronic lymphocytic leukemia, as well as some ongoing research in the field.
The top video this week included Fabrice Barlesi, MD, head of the Multidisciplinary Oncology and Therapeutic Innovations Department at Aix-Marseille University and the Assistance Publique Hôpitaux de Marseille, France, where he discussed the importance of molecular testing in patients withNSCLC
Functional High Risk and Bridging in Multiple Myeloma Considered With CAR T Cells
October 9th 2024Samer A. Al'Hadidi, MD, MS, reviewed the benefits of cilta-cel in the subgroup analysis of CARTITUDE-4 in patients with relapsed/refractory multiple myeloma and functional high risk, bridging to cilta-cel, and time to treatment in the second article of a 2-part series.
Read More